Al-Ani I - Search Results

1

Development and Evaluation of a Cost-Effective, Carbon-Based, Extended-Release Febuxostat Tablet.

Al-Ani IH, Hailat M, Mohammed DJ, Matalqah SM, Abu Dayah AA, Majeed BJM, Awad R, Filip L, Abu Dayyih W. Al-Ani IH, et al. Molecules. 2024 Sep 29;29(19):4629. doi: 10.3390/molecules29194629. Molecules. 2024. PMID: 39407557 Free PMC article.

2

Solubility, pH-Solubility Profile, pH-Rate Profile, and Kinetic Stability of the Tyrosine Kinase Inhibitor, Alectinib.

Madlool DT, Al-Ani I, Ata T, Dayyih WA. Madlool DT, et al. Among authors: al ani i. Pharmaceuticals (Basel). 2024 Jun 13;17(6):776. doi: 10.3390/ph17060776. Pharmaceuticals (Basel). 2024. PMID: 38931444 Free PMC article.

3

Evaluation of Solubility, Dissolution Rate, and Oral Bioavailability of β-Cyclodextrin and Hydroxypropyl β-Cyclodextrin as Inclusion Complexes of the Tyrosine Kinase Inhibitor, Alectinib.

Majeed BJM, Saadallah MA, Al-Ani IH, El-Tanani MK, Al Azzam KM, Abdallah HH, Al-Hajji F. Majeed BJM, et al. Among authors: al ani ih. Pharmaceuticals (Basel). 2024 Jun 5;17(6):737. doi: 10.3390/ph17060737. Pharmaceuticals (Basel). 2024. PMID: 38931404 Free PMC article.

4

Enhancement of apixaban's solubility and dissolution rate by inclusion complex (β-cyclodextrin and hydroxypropyl β-cyclodextrin) and computational calculation of their inclusion complexes.

Salman ZN, Al-Ani I, Al Azzam KM, Majeed BJM, Abdallah HH, Negim ES. Salman ZN, et al. Among authors: al ani i. ADMET DMPK. 2023 Aug 10;11(4):533-550. doi: 10.5599/admet.1885. eCollection 2023. ADMET DMPK. 2023. PMID: 37937243 Free PMC article.

5

The Formulation and Evaluation of Deep Eutectic Vehicles for the Topical Delivery of Azelaic Acid for Acne Treatment.

Luhaibi DK, Ali HHM, Al-Ani I, Shalan N, Al-Akayleh F, Al-Remawi M, Nasereddin J, Qinna NA, Al-Adham I, Khanfar M. Luhaibi DK, et al. Among authors: al ani i. Molecules. 2023 Oct 4;28(19):6927. doi: 10.3390/molecules28196927. Molecules. 2023. PMID: 37836770 Free PMC article.

6

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats.

Jaber A, Al-Ani I, Hailat M, Daoud E, Abu-Rumman A, Zakaraya Z, Majeed BJM, Al Meanazel O, Dayyih WA. Jaber A, et al. Among authors: al ani i. Heliyon. 2022 Oct 12;8(10):e11015. doi: 10.1016/j.heliyon.2022.e11015. eCollection 2022 Oct. Heliyon. 2022. PMID: 36281394 Free PMC article.

7

On-chip low-loss all-optical MoSe₂ modulator.

Alaloul M, Khurgin JB, Al-Ani I, As'ham K, Huang L, Hattori HT, Miroshnichenko AE. Alaloul M, et al. Among authors: al ani i. Opt Lett. 2022 Aug 1;47(15):3640-3643. doi: 10.1364/OL.465171. Opt Lett. 2022. PMID: 35913277

8

Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions.

Hailat M, Zakaraya Z, Al-Ani I, Meanazel OA, Al-Shdefat R, Anwer MK, Saadh MJ, Abu Dayyih W. Hailat M, et al. Among authors: al ani i. Pharmaceuticals (Basel). 2022 Feb 3;15(2):193. doi: 10.3390/ph15020193. Pharmaceuticals (Basel). 2022. PMID: 35215305 Free PMC article.

9

Role of Micro-RNA in the Regulation of Cell Polarization in Hepatocellular Carcinoma.

Al-Ani INT, Al-Ani HA. Al-Ani INT, et al. Hum Gene Ther. 2022 Mar;33(5-6):301-308. doi: 10.1089/hum.2021.280. Hum Gene Ther. 2022. PMID: 34963332

10

Synthesis and characterization of mesoporous silica and its application as drug delivery system for glimepiride.

Muhana F, Al-Ani I, Al-Akayleh F, Marzouqa D, Khalili F, Al-Khatib H, Mutti H, Shalan N. Muhana F, et al. Among authors: al ani i. Pharmazie. 2021 Jul 1;76(7):300-307. doi: 10.1691/ph.2021.1309. Pharmazie. 2021. PMID: 34256891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters